Literature DB >> 9409643

Protection against anti-glomerular basement membrane (GBM)-mediated nephritis in C3- and C4-deficient mice.

N S Sheerin1, T Springall, M C Carroll, B Hartley, S H Sacks.   

Abstract

Mice rendered completely deficient of the complement components C3 or C4 were used to determine the influence of complement activation in the heterologous phase of the anti-GBM disease model. In wild-type animals the disease is characterized by a neutrophil infiltrate, capillary thrombosis, proteinuria and C3 and C4 deposited within the glomerulus. The early infiltration of neutrophils into the glomeruli is greater in wild-type mice (2.8 +/- 0.3) compared with C3-deficient (1.4 +/- 0.2) and C4-deficient (1.2 +/- 0.003) mice. Deficiency also protects against the subsequent development of proteinuria (2.99 +/- 1.11 mg/24h, 0.059 mg/24h and 0.327 +/- 0.14 mg/24h in wild-type, C3-deficient and C4-deficient mice, respectively) and decreases glomerular capillary thrombosis in both C3- and C4-deficient mice. The degree of protection is greater in the C3-deficient than the C4-deficient animals, suggesting both classical and alternative pathway involvement. These studies support a critical role for complement in the development of anti-GBM disease. However, the protective effect of complement deficiency can be broken if the dose of nephritogenic antibody is increased.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9409643      PMCID: PMC1904827          DOI: 10.1046/j.1365-2249.1997.4261438.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

1.  Fc gamma RIII and Fc gamma RIV are indispensable for acute glomerular inflammation induced by switch variant monoclonal antibodies.

Authors:  Angela Giorgini; Heather J Brown; Helen R Lock; Falk Nimmerjahn; Jeffrey V Ravetch; J Sjef Verbeek; Steven H Sacks; Michael G Robson
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

Review 2.  ANCA-negative pauci-immune crescentic glomerulonephritis.

Authors:  Min Chen; Cees G M Kallenberg; Ming-Hui Zhao
Journal:  Nat Rev Nephrol       Date:  2009-04-28       Impact factor: 28.314

Review 3.  Review: Complement and its regulatory proteins in kidney diseases.

Authors:  Allison M Lesher; Wen-Chao Song
Journal:  Nephrology (Carlton)       Date:  2010-10       Impact factor: 2.506

4.  Novel therapy for anti-glomerular basement membrane disease with IgA nephropathy: A case report.

Authors:  Dechao Xu; Jianxiang Wu; Jun Wu; Chenggang Xu; Yuqiang Zhang; Changlin Mei; Xiang Gao
Journal:  Exp Ther Med       Date:  2016-03-11       Impact factor: 2.447

5.  The tetraspanin CD37 protects against glomerular IgA deposition and renal pathology.

Authors:  Angelique L Rops; Carl G Figdor; Alie van der Schaaf; Wim P Tamboer; Marinka A Bakker; Jo H Berden; Henry B P M Dijkman; Eric J Steenbergen; Johan van der Vlag; Annemiek B van Spriel
Journal:  Am J Pathol       Date:  2010-03-26       Impact factor: 4.307

6.  The complement inhibitors Crry and factor H are critical for preventing autologous complement activation on renal tubular epithelial cells.

Authors:  Brandon Renner; Kathrin Coleman; Ryan Goldberg; Claudia Amura; Amanda Holland-Neidermyer; Kathryn Pierce; Heather N Orth; Hector Molina; Viviana P Ferreira; Claudio Cortes; Michael K Pangburn; V Michael Holers; Joshua M Thurman
Journal:  J Immunol       Date:  2010-07-30       Impact factor: 5.422

Review 7.  Update on crescentic glomerulonephritis.

Authors:  Carole Hénique; Christina Papista; Léa Guyonnet; Olivia Lenoir; Pierre-Louis Tharaux
Journal:  Semin Immunopathol       Date:  2014-06-20       Impact factor: 9.623

Review 8.  Complement regulation and kidney diseases: recent knowledge of the double-edged roles of complement activation in nephrology.

Authors:  Masashi Mizuno; Yasuhiro Suzuki; Yasuhiko Ito
Journal:  Clin Exp Nephrol       Date:  2017-03-24       Impact factor: 2.801

Review 9.  Cutting edge issues in Goodpasture's disease.

Authors:  Andrew L Chan; Samuel Louie; Kevin O Leslie; Maya M Juarez; Timothy E Albertson
Journal:  Clin Rev Allergy Immunol       Date:  2011-10       Impact factor: 8.667

10.  Novel targets for immunotherapy in glomerulonephritis.

Authors:  Mary H Foster
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.